Table 1.
Patient baseline characteristics.
| Pt* | Age (Years) | Sex | ALT (U/L) | AST (U/L) | Hepatic stiffness (kPa) | HBsAg (IU/mL) | HBV DNA (IU/mL) | HBcrAg (log U/mL) | HDV RNA (U/mL) | Duration of HDV infection before treatment |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 33 | F | 188 | 160 | 8.4 | 13988 | <10 | <LLoD | 3.94 × 105 | 1 year, 5 months |
| 2 | 29 | F | 98 | 64 | 7.7 | 27264 | <10 | <LLoD | 4.71 × 107 | 3 years, 6 months |
| 3 | 40 | M | 53 | 36 | 14.8 | 28261 | <10 | <LLoD | 6.97 × 105 | 18 years |
| 6 | 37 | M | 95 | 54 | 6.8 | 17511 | 726 | 4.1 | 5.49 × 106 | 12 years |
| 9 | 22 | M | 85 | 55 | 12 | 16426 | 104 | 4.4 | 2.11 × 105 | 4 years, 7 months |
| 11 | 35 | M | 200 | 85 | 9.6 | 12382 | <10 | 3.2 | 1.21 × 107 | 9 years |
| 14 | 32 | M | 143 | 64 | 11.6 | 20869 | <10 | <LLoD | 2.30 × 107 | 6 years, 1 month |
| 17 | 34 | M | 62 | 44 | 9.5 | 8314 | 350 | <LLoD | 1.69 × 106 | 10 months |
| 20 | 44 | F | 29 | 27 | 8.8 | 13430 | <10 | 4.5 | 2.74 × 104 | 12 years |
| 22 | 36 | M | 101 | 78 | 11.9 | 7836 | 16 | 5 | 1.09 × 106 | 1 year, 6 months |
| 24 | 39 | M | 160 | 88 | 7.8 | 20473 | <10 | 2.8 | 1.89 × 106 | 4 years, 10 months |
| 26 | 39 | M | 85 | 61 | 30.7 | 5854 | 256 | 4.5 | 3.76 × 106 | 9 years |
| Median | 36 | - | 96 | 62 | 9.6 | 15207 | <10 | 3 | 1.79 × 106 | 5 years 6 months |
All patients were infected with hepatitis D virus (HDV) genotype 1, negative for hepatitis B e antigen (HBeAg), and positive for anti-HBe. *, patient number as previously reported;8 TND, target not detected; LLoQ, lower limit of quantification; LLoD, lower limit of detection; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBsAg, hepatitis B surface antigen; HBcrAg, hepatitis B core-related antigen.